HighTower Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

HighTower Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-82,000	Closed	-$33K	–	3481
2022 Q2	$33K	Buy	82,000 +81,470	+15,372%	+$141K	﹤0.01%	2958
2022 Q1	$24K	Buy	+530	New	+$1.65K	﹤0.01%	3152
2021 Q3	–	Sell	-52,900	Closed	-$51K	–	3509
2021 Q2	$51K	Buy	+52,900	New	+$421K	﹤0.01%	2890
2021 Q1	–	Sell	-250	Closed	-$24K	–	3323
2020 Q4	$24K	Sell	250 -4,750	-95%	-$38.2K	﹤0.01%	2469
2020 Q3	$7K	Sell	5,000 -3,000	-38%	-$27.5K	﹤0.01%	2451
2020 Q2	$17K	Sell	8,000 -6,000	-43%	-$23K	﹤0.01%	2279
2020 Q1	$5K	Sell	14,000 -19,000	-58%	-$54.7K	﹤0.01%	2149
2019 Q4	$9K	Buy	+33,000	New	+$78.7K	﹤0.01%	2205

Other funds holding SRNE

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

OFA

Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return

CGA

Crescent Grove Advisors Lake Forest, Illinois $1.04B AUM 17.78% 1-Year Est. Return

LCM

Lattice Capital Management Kirkland, Washington $56.9M AUM 49.15% 1-Year Est. Return

STB

S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return

GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return

HFRG

Houlihan Financial Resource Group Ashburn, Virginia $257M AUM 14.19% 1-Year Est. Return

VFA

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return

GBWM

Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

HighTower Advisors's SRNE Position: Q1 2023 in Review

HighTower Advisors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 35,512 shares — an estimated $30K sold.

HighTower Advisors first reported a position in SRNE in Q3 2016 and held it in 17 quarters. The position peaked at $291K in Q1 2021. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

HighTower Advisors reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
HighTower Advisors sold 35,512 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $30K.
HighTower Advisors first reported a position in Sorrento Therapeutics, Inc. in Q3 2016 and held it in 17 quarters.
HighTower Advisors's Sorrento Therapeutics, Inc. position peaked at $291K in Q1 2021.
34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on HighTower Advisors's 13F filing for Q1 2023, filed 12 May 2023.